Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Veru stock

Learn how to easily invest in Veru stock.

Veru Inc
+ $0.38 ( + 3.54%)

Veru Inc is a biotechnology business based in the US. Veru shares (VERU) are listed on the NASDAQ and all prices are listed in US Dollars. Veru employs 252 staff and has a trailing 12-month revenue of around $52.4 million.

How to buy shares in Veru

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VERU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Veru stock price (NASDAQ: VERU)

Use our graph to track the performance of VERU stocks over time.

Veru shares at a glance

Information last updated 2022-09-25.
Latest market close$10.73
52-week range$4.34 - $24.55
50-day moving average $14.86
200-day moving average $10.15
Wall St. target price$35.20
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.35

Buy Veru shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Veru stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Veru price performance over time

Historical closes compared with the close of $10.73 from 2022-09-26

1 week (2022-09-21) 0.19%
1 month (2022-08-26) -35.63%
3 months (2022-06-28) -9.14%
6 months (2022-03-28) 107.95%
1 year (2021-09-28) 21.11%
2 years (2020-09-28) 306.44%
3 years (2019-09-27) 413.40%
5 years (2017-09-28) 303.38%

Veru financials

Revenue TTM $52.4 million
Gross profit TTM $47.9 million
Return on assets TTM -14.83%
Return on equity TTM -34.62%
Profit margin -89.77%
Book value $1.46
Market capitalisation $819.1 million

TTM: trailing 12 months

Veru share dividends

We're not expecting Veru to pay a dividend over the next 12 months.

Veru share price volatility

Over the last 12 months, Veru's shares have ranged in value from as little as $4.34 up to $24.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veru's is -0.4443. This would suggest that Veru's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Veru has bucked the trend.

Veru overview

Veru Inc. , an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U. N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome.

Frequently asked questions

What percentage of Veru is owned by insiders or institutions?
Currently 19.463% of Veru shares are held by insiders and 55.663% by institutions.
How many people work for Veru?
Latest data suggests 252 work at Veru.
When does the fiscal year end for Veru?
Veru's fiscal year ends in September.
Where is Veru based?
Veru's address is: 48 NW 25th Street, Miami, FL, United States, 33127
What is Veru's ISIN number?
Veru's international securities identification number is: US92536C1036
What is Veru's CUSIP number?
Veru's Committee on Uniform Securities Identification Procedures number is: 314462102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site